OMERS ADMINISTRATION Corp Purchases Shares of 90,400 Aurinia Pharmaceuticals Inc $AUPH

OMERS ADMINISTRATION Corp purchased a new position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) in the 1st quarter, HoldingsChannel.com reports. The institutional investor purchased 90,400 shares of the biotechnology company’s stock, valued at approximately $1,340,000.

Other large investors have also modified their holdings of the company. Royal Bank of Canada increased its holdings in shares of Aurinia Pharmaceuticals by 65.3% during the first quarter. Royal Bank of Canada now owns 367,661 shares of the biotechnology company’s stock valued at $2,956,000 after acquiring an additional 145,179 shares in the last quarter. AQR Capital Management LLC boosted its stake in Aurinia Pharmaceuticals by 8.7% in the 1st quarter. AQR Capital Management LLC now owns 503,543 shares of the biotechnology company’s stock worth $4,048,000 after purchasing an additional 40,380 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Aurinia Pharmaceuticals by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,811 shares of the biotechnology company’s stock worth $642,000 after purchasing an additional 3,497 shares in the last quarter. Creative Planning grew its position in Aurinia Pharmaceuticals by 21.0% during the 2nd quarter. Creative Planning now owns 20,699 shares of the biotechnology company’s stock worth $175,000 after purchasing an additional 3,594 shares during the last quarter. Finally, Legal & General Group Plc grew its position in Aurinia Pharmaceuticals by 16.5% during the 2nd quarter. Legal & General Group Plc now owns 141,492 shares of the biotechnology company’s stock worth $1,201,000 after purchasing an additional 20,027 shares during the last quarter. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Insider Activity at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, CEO Kevin Tang acquired 206,005 shares of the company’s stock in a transaction dated Tuesday, June 2nd. The shares were acquired at an average cost of $15.28 per share, with a total value of $3,147,756.40. Following the acquisition, the chief executive officer directly owned 13,044,106 shares of the company’s stock, valued at approximately $199,313,939.68. The trade was a 1.60% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Over the last quarter, insiders have acquired 814,606 shares of company stock valued at $12,455,129. 10.40% of the stock is owned by corporate insiders.

Aurinia Pharmaceuticals Trading Up 1.5%

Aurinia Pharmaceuticals stock opened at $15.18 on Thursday. The company has a quick ratio of 5.01, a current ratio of 5.55 and a debt-to-equity ratio of 0.08. Aurinia Pharmaceuticals Inc has a 52 week low of $8.84 and a 52 week high of $19.25. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of 7.00 and a beta of 1.41. The stock has a 50-day moving average price of $15.96 and a 200 day moving average price of $15.35.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.07. Aurinia Pharmaceuticals had a net margin of 99.97% and a return on equity of 26.62%. The company had revenue of $77.71 million for the quarter, compared to the consensus estimate of $76.98 million. Sell-side analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.81 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on AUPH shares. Zacks Research cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 21st. Weiss Ratings lowered shares of Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, May 15th. One analyst has rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $17.33.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.